Literature DB >> 33282110

Updates in Psoriasis Management: Based on selected presentations from Maui Derm 2020, January 25-29, 2020, Maui, Hawaii.

Jo Ann Lequang1.   

Abstract

Entities:  

Year:  2020        PMID： 33282110      PMCID： PMC7706859     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN： 1941-2789


× No keyword cloud information.
  71 in total

1.  Development of a new formulation combining calcipotriol and betamethasone dipropionate in an ointment vehicle.

Authors:  Lene Simonsen; Gert Høy; Erik Didriksen; Jette Persson; Nina Melchior; Jens Hansen
Journal:  Drug Dev Ind Pharm       Date:  2004       Impact factor: 3.225

Review 2.  Monocyte-Derived Cells in Tissue-Resident Memory T Cell Formation.

Authors:  Kuan-Lun Chu; Nathália V Batista; Mélanie Girard; Tania H Watts
Journal:  J Immunol       Date:  2020-02-01       Impact factor: 5.422

3.  Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study.

Authors:  Amy S Paller; Ying Hong; Emily M Becker; Raul de Lucas; Maria Paris; Wendy Zhang; Zuoshun Zhang; Claire Barcellona; Peter Maes; Loretta Fiorillo
Journal:  J Am Acad Dermatol       Date:  2019-08-10       Impact factor: 11.527

4.  Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study.

Authors:  Elizabeth G Araujo; Matthias Englbrecht; Sabrina Hoepken; Stephanie Finzel; Eleni Kampylafka; Arnd Kleyer; Sarah Bayat; Verena Schoenau; Axel Hueber; Juergen Rech; Georg Schett
Journal:  Semin Arthritis Rheum       Date:  2018-06-13       Impact factor: 5.532

Review 5.  Janus kinases in immune cell signaling.

Authors:  Kamran Ghoreschi; Arian Laurence; John J O'Shea
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

Review 6.  Psoriasis and metabolic disease: epidemiology and pathophysiology.

Authors:  Rahat S Azfar; Joel M Gelfand
Journal:  Curr Opin Rheumatol       Date:  2008-07       Impact factor: 5.006

7.  Community differentiation of the cutaneous microbiota in psoriasis.

Authors:  Alexander V Alekseyenko; Guillermo I Perez-Perez; Aieska De Souza; Bruce Strober; Zhan Gao; Monika Bihan; Kelvin Li; Barbara A Methé; Martin J Blaser
Journal:  Microbiome       Date:  2013-12-23       Impact factor: 14.650

8.  A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.

Authors:  Philip J Mease; Josef S Smolen; Frank Behrens; Peter Nash; Soyi Liu Leage; Lingnan Li; Hasan Tahir; Melinda Gooderham; Eswar Krishnan; Hong Liu-Seifert; Paul Emery; Sreekumar G Pillai; Philip S Helliwell
Journal:  Ann Rheum Dis       Date:  2019-09-28       Impact factor: 19.103

9.  Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial.

Authors:  Philip J Mease; Arthur Kavanaugh; Andreas Reimold; Hasan Tahir; Jürgen Rech; Stephen Hall; Piet Geusens; Pascale Pellet; Evie Maria Delicha; Shephard Mpofu; Luminita Pricop
Journal:  RMD Open       Date:  2018-08-13

10.  Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study.

Authors:  Joshua L Lee; Premarani Sinnathurai; Rachelle Buchbinder; Catherine Hill; Marissa Lassere; Lyn March
Journal:  Arthritis Res Ther       Date:  2018-08-07       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.